Evidence map›Paper›PMID 35768828›Full record

ArticleMolecular autism2022

Deletion of Fmr1 in parvalbumin-expressing neurons results in dysregulated translation and selective behavioral deficits associated with fragile X syndrome.

Magdalena Kalinowska, Mathijs B van der Lei, Michael Kitiashvili, Maggie Mamcarz, Mauricio M Oliveira, Francesco Longo, Eric Klann

Open access · goldAbstract read
In one paragraph

Article in Molecular autism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
11.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Infant sensory gating and a developmental cascade to autistic traits and anxiety.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Magdalena KalinowskaCenter for Neural Science, New York University, New York, NY, USA.
Mathijs B van der LeiDepartment of Medical Genetics, University of Antwerp, Antwerp, Belgium.
Michael KitiashviliCenter for Neural Science, New York University, New York, NY, USA.
Maggie MamcarzCenter for Neural Science, New York University, New York, NY, USA.
Mauricio M OliveiraCenter for Neural Science, New York University, New York, NY, USA.
Francesco LongoInstitute for Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.
Eric KlannCenter for Neural Science, New York University, New York, NY, USA. ek65@nyu.edu.ORCID 0000-0001-7379-6802
New York University · USNYU Langone Health · USUniversity of Antwerp · BEUniversity of Gothenburg · SE

Funding

Translational Control in Memory and Brain DisordersR35NS122316 · NINDS · NEW YORK UNIVERSITY · PI Eric Klann · 2021 to 2026
$6.5M
Translation Regulation in Hippocampal LTP and LTDR01NS047384 · NINDS · NEW YORK UNIVERSITY · PI KLANN, ERIC · 2005 to 2020
$5.2M
eIF2alpha Phosphorylation in Synaptic Plasticity, Memory, and Brain DisordersR37NS034007 · NINDS · NEW YORK UNIVERSITY · PI KLANN, ERIC · 2014 to 2020
$3.3M
NINDS NIH HHS R01 NS047384NINDS NIH HHS R35 NS122316NINDS NIH HHS R37 NS034007
6 · The paper itself

Abstract

backgroundFragile X syndrome (FXS), the most common genetic cause of autism spectrum disorder and intellectual disability, is caused by the lack of fragile X mental retardation protein (FMRP) expression. FMRP is an mRNA binding protein with functions in mRNA transport, localization, and translational control. In Fmr1 knockout mice, dysregulated translation has been linked to pathophysiology, including abnormal synaptic function and dendritic morphology, and autistic-like behavioral phenotypes. The role of FMRP in morphology and function of excitatory neurons has been well studied in mice lacking Fmr1, but the impact of Fmr1 deletion on inhibitory neurons remains less characterized. Moreover, the contribution of FMRP in different cell types to FXS pathophysiology is not well defined. We sought to characterize whether FMRP loss in parvalbumin or somatostatin-expressing neurons results in FXS-like deficits in mice.

methodsWe used Cre-lox recombinase technology to generate two lines of conditional knockout mice lacking FMRP in either parvalbumin or somatostatin-expressing cells and carried out a battery of behavioral tests to assess motor function, anxiety, repetitive, stereotypic, social behaviors, and learning and memory. In addition, we used fluorescent non-canonical amino acid tagging along with immunostaining to determine whether de novo protein synthesis is dysregulated in parvalbumin or somatostatin-expressing neurons.

resultsDe novo protein synthesis was elevated in hippocampal parvalbumin and somatostatin-expressing inhibitory neurons in Fmr1 knockout mice. Cell type-specific deletion of Fmr1 in parvalbumin-expressing neurons resulted in anxiety-like behavior, impaired social behavior, and dysregulated de novo protein synthesis. In contrast, deletion of Fmr1 in somatostatin-expressing neurons did not result in behavioral abnormalities and did not significantly impact de novo protein synthesis. This is the first report of how loss of FMRP in two specific subtypes of inhibitory neurons is associated with distinct FXS-like abnormalities. LIMITATIONS: The mouse models we generated are limited by whole body knockout of FMRP in parvalbumin or somatostatin-expressing cells and further studies are needed to establish a causal relationship between cellular deficits and FXS-like behaviors.

conclusionsOur findings indicate a cell type-specific role for FMRP in parvalbumin-expressing neurons in regulating distinct behavioral features associated with FXS.

Indexed as

Autism Spectrum DisorderFragile X Messenger Ribonucleoprotein 1Fragile X SyndromeNeuronsAnimalsDisease Models, AnimalMiceMice, KnockoutParvalbuminsRNA, MessengerSomatostatinFmr1 protein, mouseFragile X Messenger Ribonucleoprotein 1ParvalbuminsRNA, MessengerSomatostatinAutismBehaviorFMRPFragile X syndromeInhibitory neuronsProtein synthesis

Identifiers

PMID35768828
PMCPMC9245312
OpenAlexW4283746562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.